Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritavancin in pediatric acute bacterial skin and skin structure infections
NCT05599295Phase 2Completed
- Sponsor
- Melinta Therapeutics
- Start
- Jun 2023
- Primary completion
- Nov 2025
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of oritavancin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Melinta Therapeutics. Started Jun 2023; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT05599295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599295.